pharmaphorum

MAY 17, 2021

This article appears in full in our digital magazine Deep Dive: Market Access 2021. This will help drive consistent processes, effective assessments and enable early access to high-value medicines. Read below for a sneak-peak: The reimbursement landscape in Europe is complex.

Medicine 93

Medicine Life Science Marketing Clinical Trials 93

pharmaphorum

JUNE 7, 2022

In my role as head of market access at Sanofi UK and Ireland, I strive to address challenges around matching treatment value to patient access, and I am passionate about delivering evidence to ensure patients can receive the most appropriate treatments for their condition.

Clinical Trials 52

Clinical Trials Clinical Trials Marketing Medicine 52

pharmaphorum

DECEMBER 14, 2020

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with the patients they serve, and in putting this month’s Deep Dive together it’s been great to see that so many pharma firms are now taking this to heart.

Clinical Trials 76

Clinical Trials Clinical Trials Trials Marketing 76

pharmaphorum

DECEMBER 2, 2022

With myriad new technologies and tools hitting the market, there is no doubt that digital health is transforming the way that we deliver and receive healthcare. However, as the market begins to correct itself, where does digital health go from here? Read Deep Dive: Digital Health 2022 in full.

Pharma Companies 52

Pharma Companies Vaccination Vaccine Marketing 52

pharmaphorum

OCTOBER 14, 2022

In this article, Research Partnership reviews why the path to commercialisation for the half a dozen approvals in Europe over the last few years has not been smooth, and shares feedback gathered from our payer network on the outlook for gene therapy market access in Europe, especially considering the shift to more prevalent diseases.

Gene Therapy 93

Gene Therapy Gene Marketing Medicine 93

pharmaphorum

MAY 12, 2021

This article appears in full in Deep Dive: Market Access 2021. ” • Read the full article in pharmaphorum’s Deep Dive digital magazine. For example, did they already have e-consents in place, or were they completely reliant on face-to-face and are now having to start from scratch?”

Research 75

Research Sales Marketing 75

pharmaphorum

SEPTEMBER 17, 2020

OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharma. Subscribe to future issues of Deep Dive. The post Deep Dive: Communications 2020 appeared first on. Responding to dynamic shifts in value communications.

Marketing 52

Marketing Sales Research Development 52

pharmaphorum

JUNE 4, 2021

A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to market. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Marketing 45

Marketing Life Science Production Regulation 45

pharmaphorum

OCTOBER 4, 2022

For life science companies, it is more important than ever to understand the market access landscape they are launching in and review how commercial and engagement strategies align with the needs of today’s customers.

Life Science 52

Life Science Marketing Production Sales 52

pharmaphorum

NOVEMBER 2, 2020

Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare industries. Thriving in COVID-19 with flexible marketing strategies. Subscribe to future issues of Deep Dive.

Sales 59

Sales Clinical Trials Clinical Trials Marketing 59

pharmaphorum

MARCH 22, 2022

We show how companies can leverage and create efficiencies from the full scope of available data obtainable within each of its teams, whether medical affairs, market access , or GHEORE,” says Cherian. The post Using cross-functional teams to develop a product’s value story appeared first on.

Development 52

Development Marketing Production Research 52

pharmaphorum

JUNE 14, 2021

This article appears in our free digital magazine Deep Dive: Market Access 2021. Fighting for access. Sanders has been on metreleptin treatment herself for over 10 years, and from the start has been involved in fighting for access to the drug, engaging with the pharma companies, clinical researchers, and NICE.

Drugs 105

Drugs Pharma Companies Licensing Licensing 105

pharmaphorum

MARCH 17, 2022

The global market for life sciences is changing rapidly. But when it comes to marketing new therapies, the seemingly complex nature of global markets can be intimidating, with regulatory, cultural and language insight required to commercialise a brand image across different markets.

Life Science 52

Life Science Marketing Branding Development 52

Drug Channels

OCTOBER 23, 2023

A program driven by market dynamics and led by champions of channel strategy, join now to master the complexities of pharmacy and distribution models to accelerate market access –It's all happening December 11-13, 2023. Why should you attend this pivotal event?

Pharmacy 62

Pharmacy Marketing Production Branding 62

Pharmaceutical Technology

JUNE 29, 2022

Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. In a series of data-driven deep dives, we will examine how the development of orphan drug therapies has evolved over the years, and use the FDA’s orphan drug program as a barometer of these advances.

Drugs 246

Drugs FDA Approval Marketing Development 246

pharmaphorum

FEBRUARY 26, 2021

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media. • Read the latest issue Deep Dive: Research and Development 2021 in full.

Development 59

Development Research Pharma Companies Vaccination 59

pharmaphorum

NOVEMBER 25, 2021

Why is a new access model so pressing, and has the pandemic accelerated the situation? Although the need for a change in the market access model predates the arrival of COVID-19, the pandemic has accelerated this process. The post Time for a new model in patient access appeared first on. Yes, it has.

Gene Therapy 52

Gene Therapy Genetics Medicine Gene 52

pharmaphorum

MAY 26, 2021

Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. You essentially need to take a three-by-three matrix view.

Production 52

Production Gene Therapy Marketing Gene 52

pharmaphorum

NOVEMBER 16, 2022

Regulatory and market access submissions. Here, we examine how patients view the impact from projects and their experiences of discussing impact measurement with life science companies. • Read the full article in pharmaphorum’s Deep Dive digital magazine. Clinical trial design. Product support and information.

Life Science 52

Life Science Clinical Trials Clinical Trials Medicine 52

pharmaphorum

OCTOBER 21, 2021

The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation. Overseeing all of this is as the company’s senior vice president for major markets is Catherine Owen.

Sales 52

Sales Marketing 52

pharmaphorum

MARCH 15, 2022

With digital engagement rapidly overtaking traditional models, life science teams must equip themselves with a means to engage patients in a virtual setting that’s easy to access and available when they are. Marketing Permissions. We use Mailchimp as our marketing platform. Real-world examples of patient engagement success.

Life Science 98

Life Science Compliance Marketing Production 98

pharmaphorum

MAY 10, 2021

This article appears in full in this month’s Deep Dive digital magazine on Market Access. IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. The post A year on: pandemic driven trends in HCP engagement appeared first on.

Pharma Companies 90

Pharma Companies Marketing Research 90

pharmaphorum

MAY 14, 2021

This article appears in our digital magazine, Deep Dive: Market Access 2021. This additional effort could lead to poorer patient access. “It It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE.

Marketing 59

Marketing Regulation Medicine Life Science 59

pharmaphorum

JUNE 18, 2021

This article appears in our free digital magazine Deep Dive: Market Access 2021. These included raising awareness, access to care, collaboration and innovation, and digital. The goal was to provide a platform for a global patient organisation and a meeting of groups who may have never met.

Clinical Trials 52

Clinical Trials Clinical Trials Marketing Trials 52

pharmaphorum

OCTOBER 7, 2020

OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies. Value in healthcare is a continually changing concept. The post Responding to dynamic shifts in value communications appeared first on.

Regulation 69

Regulation Marketing 69

pharmaphorum

AUGUST 4, 2022

“There has been a surge in the number of biomarkers discovered through a broader understanding of the molecular pathways involved in the development of cancer, both across solid and liquid tumours,” explains Orlaith Brennan, market development director, Patient & Market Access at IQVIA. “In

Genome 52

Genome Genomics Genome Project DNA 52

pharmaphorum

NOVEMBER 26, 2021

As companies are increasingly forced to persuade budget-holders of a drug’s cost-effectiveness to ensure post-approval market access, RWD can play a central role. The post Leveraging real-world data to meet payers’ needs appeared first on.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Pharma Companies 52

Drug Channels

OCTOBER 15, 2023

View the agenda the 2023 PBM Contracting Summit to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/pbm-contracting for further details and to register.

Insulin 56

Insulin Drugs Marketing Development 56

pharmaphorum

NOVEMBER 10, 2020

Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and Emanuele Arcà. The post Germany’s digital health changes will boost digital therapeutics in Europe appeared first on.

Medicine 72

Medicine Marketing Development 72

pharmaphorum

JANUARY 20, 2023

For millions of people around the world living with infectious disease and cancer, the arrival of a new prophylactic or therapeutic vaccine on the market can be life changing. But in order for a treatment to reach patients, it needs to be launched.

Vaccination 52

Vaccination Vaccine Medicine Marketing 52

XTalks

JULY 21, 2023

These members now have access to the advanced Iris platform, offering specialized mental health care tailored for oncology patients, 24×7 symptom management and essential nutritional support. We are excited to offer expanded access to HealthPartners members.” RELATED: care.ai

Nurses 98

Nurses Doctors Doctor Clinical Trials 98

Drug Channels

JUNE 26, 2023

View the agenda for Health Systems & Pharma Partnering 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/health-systems-partnering for further details and to register.

Life Science 63

Life Science Pharmacy Drugs Manufacturing 63

Drug Channels

AUGUST 14, 2023

Informa Connect’s Copay, Reimbursement and Access Congress Hybrid Event | October 2-4 at the Bellevue Hotel in Philadelphia, PA www.informaconnect.com/copayreimbursement Exclusive Offer: Be sure to use your exclusive promo code USAVE10 to save 10% off* of your registration. Exclusive Offer: View the agenda and register today!

Drugs 52

Drugs Marketing 52

Drug Channels

AUGUST 22, 2022

Informa Connect’s Copay, Reimbursement and Access Congress. An important event for all aspects cost sharing, Copay, Reimbursement and Access Congress is back and better than ever! Now is the time to join to drive patient assistance, adherence and access forward—it’s all happening October 12-14.

Compliance 56

Compliance Drugs Branding Production 56

Drug Channels

MARCH 6, 2023

Attorney's Office for the Districts of MA and NJ , and Viatris You'll take a deep dive into the hottest topics keeping you up at night, including Drug Pricing Transparency Pressures DOJ Drug Pricing Transparency Priorities Legal Updates on Authorized Generics and the U.S.

Drugs 84

Drugs Life Science Compliance Branding 84

pharmaphorum

JUNE 8, 2021

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”.

Marketing 105

Marketing Drugs Regulation Development 105

pharmaphorum

JUNE 22, 2021

This article appears in our free digital magazine Deep Dive: Market Access 2021. So we try and invite different people to every meeting we’ve done and come up with tangible goals from them.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine. Read below for a preview.

Insulin 52

Insulin Production Marketing Development 52